Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial - Concepedia

Concepedia

Publication | Open Access

Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial

DOI Full Paper Access

709

Citations

26

References

2021

Year

Ben M. Eyck, J. Jan B. van Lanschot, Maarten C.C.M. Hulshof, Berend J. van der Wilk, Joël Shapiro, Pieter van Hagen, Mark I. van Berge Henegouwen, Bas P. L. Wijnhoven, Hanneke W. M. van Laarhoven, Grard A. P. Nieuwenhuijzen,

Journal of Clinical Oncology

Abstract

The overall survival benefit of patients with locally advanced resectable esophageal or junctional cancer who receive preoperative chemoradiotherapy according to CROSS persists for at least 10 years.

References

	Year	Citations

Page 1